comparemela.com

Latest Breaking News On - Defense medical research - Page 3 : comparemela.com

The U S Department of Defense Awards CytoSorbents an Approximately $2 0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma

Anatomy of an extensively drug-resistant Klebsiella pneumoniae outbreak in Tuscany, Italy

Carbapenem-resistant Klebsiella pneumoniae belongs to the “critical-priority” tier of bacterial pathogens as identified by the World Health Organization. Emerging “high-risk” lineages are responsible for difficult-to-treat, hospital-acquired infections and outbreaks around the globe. By integrating genomic and epidemiological data for isolates collected over 20 mo, this study revealed both the high, regional prevalence and the rapid spread, within a single hospital, of K. pneumoniae ST-147 in Italy. Besides resistance to nearly all antibiotics, this lineage carried a hybrid plasmid harboring a set of biomarker genes previously linked to hypervirulence. Convergence of resistance and virulence determinants is a major concern and these findings highlight the need for robust, global surveillance to monitor the emergence of high-risk K. pneumoniae .

Lupus Foundation of America : Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis

Lupus Foundation of America : Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Lupus Foundation of America Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis

Lupus Foundation of America Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis News provided by Share this article Share this article WASHINGTON, Dec. 17, 2020 /PRNewswire/ The U.S. Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Up to 60 percent of people with lupus will develop lupus nephritis. Benlysta is a human monoclonal antibody sold by GSK. The FDA first approved Benlysta for lupus in 2011. However, at that time, Benlysta had not been studied for use in individuals with severe lupus nephritis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.